A partial agonist of PPARγ prevents paclitaxel-induced peripheral neuropathy in mice, by inhibiting neuroinflammation.

BACKGROUND AND PURPOSE: Chemotherapy-induced peripheral neuropathy (CIPN) is a common side effect of paclitaxel, affecting 30-50% of patients. Increased survival and concern with patients' quality of life have encouraged the search for new tools to prevent paclitaxel-induced neuropathy. This study presents the glitazone 4-[(Z)-(2,4-dioxo-1,3-thiazolidin-5-ylidene)methyl]-N-phenylbenzene-sulfonamide (TZD-A1) as a partial agonist of peroxisome proliferator-activated receptor γ (PPARγ), its toxicological profile and effects on paclitaxel-induced CIPN in mice. EXPERIMENTAL APPROACH: Interactions of TZD-A1 with PPARγ were analysed using in silico docking and in vitro reporter gene assays. Pharmacokinetics and toxicity were evaluated using in silico, in vitro and in vivo (C57Bl/6 mice) analyses. Effects of TZD-A1 on CIPN were investigated in paclitaxel-injected mice. Axonal and dorsal root ganglion damage, mitochondrial complex activity and cytokine levels, brain-derived neurotrophic factor (BDNF), nuclear factor erythroid 2-related factor 2 (Nrf2) and PPARγ, were also measured. KEY RESULTS: Docking analysis predicted TZD-A1 interactions with PPARγ compatible with partial agonism, which were corroborated by in vitro reporter gene assays. Good oral bioavailability and safety profile of TZD-A1 were shown in silico, in vitro and in vivo. Paclitaxel-injected mice, concomitantly treated with TZD-A1 by i.p. or oral administration, exhibited decreased mechanical and thermal hypersensitivity, effects apparently mediated by inhibition of neuroinflammation and mitochondrial damage, through increasing Nrf2 and PPARγ levels, and up-regulating BDNF. CONCLUSION AND IMPLICATIONS: TZD-A1, a partial agonist of PPARγ, provided neuroprotection and reduced hypersensitivity induced by paclitaxel. Allied to its safety profile and good bioavailability, TZD-A1 is a promising drug candidate to prevent and treat CIPN in cancer patients.

What does not kill mesangial cells makes it stronger? The response of the endoplasmic reticulum stress and the O-GlcNAc signaling to ATP depletion.

Mesangial cells are modified smooth muscle cells with the ability to modulate glomerular filtration rate (GFR) - a marker of ischemic renal injury. We aimed to determine the role of intracellular O-GlcNAc levels and ER stress in mesangial cells subjected to ATP depletion. Immortalized mouse mesangial cells culture was incubated for 30, 45 and 60 min, or not (control group) with a buffer containing antimycin A and 2-deoxy-d-glucose, inhibitors of ATP synthesis. Mesangial cells subjected to ATPdepletion for 45 min followed by 24 h reperfusion (H45/R24 mesangial cells) promoted 30 % of cell death mainly by necrosis. ATP depletion was sustained throughout reperfusion until 24 h. Resistant H45/R24 mesangial cells presented: (i) low protein content of GFAT, OGT and OGA, however no modification of total O-GlcNAcylation and (ii) attenuation of protein synthesis related to a UPR response mediated by GRP78/PERK/p-eIF2α and a decrease in the protein content of ATF4. The lower activation of apoptosis was related to no alterations in the levels of CHOP and activated caspase 3. We also detected activation of intracellular mediators of necroptosis: IRE1, ATF6, GADD34, ERO1, Mdm2 and P53. The resistant H45/R24 mesangial cells can replenish the cell culture dish indicating that the UPR adaptative response permitted cell survival. Successive ATP depletion induced lower levels O-GlcNAcylation leading to a 30 % cell death in every H/R process. We concluded that lower levels of O-GlcNAcylation and the GRP78/PERK/p-eIF2α UPR response are the molecular mechanisms involved in H45/R24 mesangial cell survival.